Pharmaceutical Technology

DECEMBER 16, 2022

This growth is primarily due to market release of several gonadotropin-releasing hormone (GnRH) receptor antagonists, including Myovant’s Myfembree (relugolix, estradiol, and norethindrone acetate) in the US, and its upcoming launch in the 5EU, where it will be sold under the brand name Ryeqo. of 7MM sales.

Marketing 147

Marketing Hormones Sales Branding 147

pharmaphorum

MAY 27, 2021

It is thought that around five million women in the US have uterine fibroids that cause symptoms, with two-thirds of them inadequately treated with current drugs – generally off-label oral contraceptives or injectable gonadotropin releasing hormone (GnRH) agonists like leuprolide acetate or goserelin acetate.

Hormones 98

Hormones Sales Marketing Drugs 98

Pharmaceutical Technology

OCTOBER 13, 2022

The hormone is produced endogenously in the body by the pineal gland. When light is detected by the retina, it causes the pineal gland to inhibit melatonin release, preventing the feelings of sleepiness associated with the hormone. In 1995, the UK government classified it as a medicine making its over-the-counter sale illegal.

Drugs 147

Drugs Hormones Sales Medicine 147

pharmaphorum

AUGUST 30, 2022

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its therapeutic focus further into hormonal disorders. In July, Diurnal reported product sales of around £2.3 Shares in the UK firm had leaped 132% to 26.1

Hormones 105

Hormones Sales Clinical Trials Clinical Trials 105

pharmaphorum

SEPTEMBER 15, 2021

If approved, linzagolix will be the only drug in the class with a dosing regimen intended for women with uterine fibroids who cannot or do not want to take hormone therapy, as well as options for those women happy to do so, according to ObsEva.

Hormones 98

Hormones Drugs FDA Approval Sales 98

pharmaphorum

MARCH 23, 2021

The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales predicted for the drug if it makes it to market. Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1

Trials 124

Trials Hormones Sales Drugs 124

Pharmaceutical Technology

MAY 25, 2023

Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties. The deal includes licence income for specified individual key markets along with profit sharing on future Mellozzan sales.

Hormones 130

Hormones Engineer Containment Licensing 130

pharmaphorum

AUGUST 3, 2022

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.

Sales 105

Sales Hormones Drugs Antibody 105

XTalks

MARCH 18, 2025

Standard treatment strategies include combinations of antibiotics, hormonal therapies and biologic agents most notably adalimumab (Humira), the only FDA-approved biologic for moderate to severe cases while surgery remains an option for advanced disease.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

pharmaphorum

FEBRUARY 21, 2022

It’s a key moment for the two companies, as expansion into HER2-low breast cancer has been held up as a key requirement for Enhertu (trastuzumab deruxtecan) if it is to achieve its multibillion-dollar sales expectations. billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved.

Trials 132

Trials Sales Hormones Drugs 132

XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. Late last year, Zepbound brought in $1.26

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

pharmaphorum

AUGUST 15, 2022

At this year’s ASCO congress, the Trop2-targeting antibody-drug conjugate (ADC) was found to improve progression-free survival significantly in in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment.

HR 90

HR Hormones Sales Antibody 90

pharmaphorum

AUGUST 16, 2022

The study – which included an all-comer population of men with mCRPC – showed that Lynparza plus Johnson & Johnson’s hormonal therapy Zytiga (abiraterone) reduced the risk of disease progression or death by 34% versus Zytiga alone, with radiographic progression-free survival (rPFS) of 24.8 months and 16.6 months, respectively.

Hormones 111

Hormones Gene Sales Trials 111

pharmaphorum

DECEMBER 3, 2021

When this happens, the first line of drug treatment if the tumours are hormone-sensitive is ADT, with chemotherapy layered on top if needed. Around 95% of prostate cancers are localised at diagnosis and treated with surgery or radiotherapy, but tend to relapse.

Trials 107

Trials Sales Hormones Drugs 107

XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.

Insulin 98

Insulin Hormones FDA Approval Sales 98

pharmaphorum

MARCH 10, 2022

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil its aim of €3 billion in peak sales for the drug.

Hormones 81

Hormones Sales Drugs Marketing 81

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

Pharmaceutical Technology

JUNE 6, 2023

Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV).

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

pharmaphorum

AUGUST 11, 2020

A phase 3 trial is expected to begin in 2021 and the company says that the compound could generate peak sales of more than a billion euros globally. At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats.

Drugs 98

Drugs Hormones Marketing Trials 98

Pharmaceutical Technology

APRIL 19, 2023

In 2012, Bayer entered a five-year, multi-target collaboration with Evotec which yielded six non-hormonal pre-clinical candidates, two of which advanced to Phase I development: BAY2328065 and BAY2395840.

Gene Therapy 130

Gene Therapy Hormones Production Sales 130

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

SEPTEMBER 8, 2022

The information contained within the download document is intended for pharmacists, pharmaceutical executives, sales managers, manufacturers, business development managers, pharmaceutical sales representatives, and any other individual involved in the pharmaceutical compounding sector. . • Test method development.

Marketing 100

Marketing Pharmacy Containment Sales 100

pharmaphorum

MARCH 8, 2021

The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies abiraterone and enzalutamide but have relapsed.

Hormones 98

Hormones Marketing Trials DNA 98

XTalks

NOVEMBER 3, 2022

Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Price of Revlimid: A supply of 28 oral 2.5 mg capsules is $24,576.

FDA Approval 101

FDA Approval Drugs Sales Development 101

pharmaphorum

APRIL 25, 2022

The Swiss pharma said in its update that the acelERA trial comparing giredestrant to physician’s choice of endocrine therapy for previously-treated hormone receptor (HR)-positive, HER2-negative breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). Ocrevus rose 18% to CHF 1.4

Trials 69

Trials Hormones HR Sales 69

XTalks

JULY 19, 2024

The meteoric rise in the popularity of GLP-1 medications has created a breeding ground for online scams and the sale of unauthorized products,” said LegitScript CEO Scott Roth in a press release.

Pharmacy 104

Pharmacy Drugs Production Sales 104

pharmaphorum

AUGUST 8, 2022

The US regulator has approved Nubeqa (darolutamide) in combination with docetaxel chemotherapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), adding to its earlier indication in non-metastatic castration-resistant prostate cancer (nmCRPC). billion) blockbuster.

Sales 59

Sales Hormones Marketing FDA Approval 59

pharmaphorum

OCTOBER 11, 2020

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s rival drug Verzenio.

Trials 52

Trials HR Hormones Drugs 52

pharmaphorum

JUNE 4, 2021

Those include studies in the pre-chemotherapy setting in CRPC, as well as in metastatic hormone-sensitive prostate cancer (HSPC) patients who are treatment-naïve or with only short-term use of standard first-line hormonal therapies. The drug made $445 million in sales last year.

Hormones 88

Hormones Licensing Licensing Drugs 88

Pharmaceutical Technology

FEBRUARY 14, 2023

The company filed heterocyclic composition patents in areas such as PAD4 inhibitors, factor Xa inhibitors, and nuclear hormone receptor modulators. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

pharmaphorum

MARCH 24, 2022

Studies are on the go in the pre-chemotherapy setting in CRPC, as well as in metastatic hormone-sensitive prostate cancer (HSPC) patients who are treatment-naïve or with only short-term use of standard first-line hormonal therapies.

Hormones 59

Hormones Sales FDA Approval Drugs 59

XTalks

MARCH 8, 2021

billion in sales last year, making it the company’s biggest revenue generator in 2020. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

The Pharma Data

AUGUST 11, 2020

After this, the agreement promises further “triple digit million” milestone payments to be made once sales goals are hit. It has been projected that, if successful, the drug could rake in as much as €1 billion in global sales at its peak. The deal is expected to close by September this year. Matt Fellows. Source link.

Hormones 52

Hormones Sales Medicine Development 52